Allergen, Individual-Food Kiwi Fruit Actinidia deliciosa F84

The Allergen, Individual-Food Kiwi Fruit (Actinidia deliciosa) F84 test is a targeted blood assay that detects specific IgE antibodies to kiwi, indicating IgE‑mediated sensitisation to Actinidia deliciosa. Performed using a validated immunoassay on a capillary or venous sample collected at home or at a lab, the test provides a quantitative measurement (kU/L) and a standard sensitisation class to help determine allergic risk.

This test is important for distinguishing true allergic sensitisation from non‑immune food intolerance and for risk stratification of reactions ranging from oral allergy syndrome to systemic anaphylaxis. Results support clinical decisions such as elimination diets, supervised food challenges, prescription of emergency treatment (e.g., epinephrine), and discussion of cross‑reactivity (for example with latex or other fruit allergens); interpretation and next‑step recommendations are provided by the laboratory or an allergist in Dubai/UAE.

• Kiwi (Actinidia deliciosa) — Specific IgE
• Act d 1 (actinidin) — Allergen component specific IgE
• IgE concentration (kU/L) and sensitisation class (0–6)

• Immediate allergic symptoms after eating kiwi (hives, swelling, throat tightness)
• Oral allergy syndrome (itching or tingling in mouth or throat after kiwi)
• History of anaphylaxis or systemic reaction following kiwi ingestion
• Suspected cross‑reactivity with latex or other fruit allergies
• Prior to supervised food challenge or planned dietary reintroduction

• Accurate quantitative detection of kiwi‑specific IgE for clear sensitisation assessment
• Convenient at‑home sample collection across Dubai and the UAE
• Component information (Act d 1) to refine risk and cross‑reactivity evaluation
• Personalised result interpretation and guidance for allergy management
• Helps avoid unnecessary broad dietary restrictions while improving safety planning

• At‑home capillary (finger‑prick) or clinic venous blood collection kit provided
• No fasting required; normal diet may be maintained before sampling
• Inform provider about current medications, recent immunotherapy, or recent severe reactions
• Provide accurate patient details and a Dubai/UAE address for home collection and reporting